Menu

Pharma News

picture 83

Aurobindo forms generics joint venture with Russia’s Diod

Home/Pharma News | Posted 21/10/2011

India-based Aurobindo Pharma (Aurobindo) announced on 7 September 2011 that it had formed a joint venture with Russian company Ojsc Diod (Diod) to manufacture and sell pharmaceutical products in Belarus, Kazakhstan and Russia.

picture 71

Pfizer and US pharmacies fight counterfeit medicines

Home/Pharma News | Posted 07/10/2011

Pfizer and the US National Association of Boards of Pharmacy (NABP) announced on 29 September 2011 that they have launched a new effort to draw attention to the risks associated with counterfeit drugs and to help patients learn how to buy medicines online safely.

picture 68

Sun Pharma’s US operations partially on track

Home/Pharma News | Posted 07/10/2011

Sun Pharma announced on 19 September 2011 that its US arm has resolved issues raised by the country’s health regulator regarding violation of manufacturing standards.

picture 63

Authorised generics implicated in pay-to-delay deals

Home/Pharma News | Posted 30/09/2011

A US Federal Trade Commission (FTC) report has found that authorised generics may reduce generics competition. The report also shows that some originator companies may have used agreements not to launch an authorised generic drug as a way to compensate would-be generic competitors for delaying entry into the market.

picture32

Eli Lilly in deal with Turkish generics company

Home/Pharma News | Posted 09/09/2011

American drugmaker Eli Lilly is in talks to form a partnership with, and potentially invest in, Turkish generic drugs company Mustafa Nevzat İlaç Sanayii A.Ş. (MN Pharmaceuticals), according to a Wall Street Journal report from 2 September 2011.

picture24

Medivir subsidiary BioPhausia sells generics business

Home/Pharma News | Posted 02/09/2011

Sweden-based Medivir announced on 25 August 2011 that its subsidiary BioPhausia had reached an agreement to sell its generics business (BMM Pharma) to Bluefish Pharmaceuticals (Bluefish) for SEK 26 million plus the value of inventories, some SEK 12 million. The staff of BMM Pharma will not be transferred in the acquisition.

picture23

GaBI Online launches its country focus section

Home/Pharma News | Posted 02/09/2011

- Provides Easy to Find Country Specific Information -

FIRST IN THE SPOTLIGHT – BELGIUM, THE NETHERLANDS AND UK

picture 64

Generics of antibiotic Levaquin approved by FDA

Home/Pharma News | Posted 01/07/2011

The FDA has approved the first generic versions of Johnson and Johnson’s (J&J) blockbuster antibiotic Levaquin (levofloxacin), used to treat bacterial infections of the skin, sinuses, kidneys, bladder, and prostate caused by specific germs.

Record high drug shortages in the US

Home/Pharma News | Posted 17/06/2011

In 2010, there were 178 drugs that experienced shortages in the US, see Figure 1. This is a record high level and regulators blame quality and manufacturing problems for the crisis. Worse still, many of the drugs identified in 2010 remain unavailable or in short supply in 2011.

picture41

Watson buys Greek generic maker Specifar

Home/Pharma News | Posted 10/06/2011

Watson Pharmaceuticals announced on 25 May 2011 that it had bought the Greece-based generic manufacturer Specifar Pharmaceuticals for Euros 400 million with the intention of increasing its generics presence in Europe.

picture33

Pay-to-delay deals up by 60% in US

Home/Pharma News | Posted 06/06/2011

The number of deals struck between brand-name and generic pharmaceutical companies in the US are on the rise, despite efforts by the US Federal Trade Commission (FTC) to restrict agreements that delay the introduction of lower-cost medicines, according to a report from the agency.

picture28

Generics and biosimilars to drive down drug spending

Home/Pharma News | Posted 27/05/2011

A report published by IMS Health on 18 May 2011 predicts a slowing down of the growth in annual spending on medicines, with generics being one of the main contributing factors for this reduction.

picture24

Teva expands in Japan – buying generic’s maker Taiyo

Home/Pharma News | Posted 27/05/2011

Teva is on the prowl again—grabbing yet another smaller generics manufacturer—and increasing its presence in the lucrative Japanese market. The Israeli generics giant announced on 16 May 2011 that it had agreed to buy a 57% stake in Japan-based Taiyo Pharmaceutical Industry for US$460 million.

picture15

Teva finally gets troubled Irvine plant back in action

Home/Pharma News | Posted 20/05/2011

Teva told the Wall Street Journal, on 3 May 2011 that its injectables facility in the US, which was shut down a year ago after quality control problems, has now received the green light from the FDA and has restarted production.

picture 78

Teva – a moving target

Home/Pharma News | Posted 15/04/2011

Teva Pharmaceutical Industries has grown rapidly since the forerunner of today’s firm was born in 1976. It has achieved its vision of becoming the world’s number one generics manufacturer, or as it puts it ‘its commitment to providing consumers with access to high-quality, affordable medicines’. It takes a great many legal wrangles and much forward planning to maintain this position.

picture 79

China to power global generics development

Home/Pharma News | Posted 15/04/2011

Analysts estimate that China will overtake France and Germany as the world’s third-largest prescription medicines market in 2012, trailing only the US and Japan.

picture 69

The latest on healthcare austerity in Greece

Home/Pharma News | Posted 08/04/2011

Greece is seeking to save approximately Euros 900 million a year and reduce the share of gross domestic product accounted for by healthcare spending from more than 10% in 2008 to under 6%. To help to achieve this, the maximum price of generic drugs will be set at no more than 60% of the originator product’s price, rather than 72% as originally proposed in September 2010.

picture 63

Hikma buying into the US market

Home/Pharma News | Posted 08/04/2011

Hikma is buying some of Baxter’s injectable products that are sold primarily in the US, including chronic pain, anti-infective and anti-emetic products, along with the Cherry Hill manufacturing facility and the Memphis warehouse and distribution centre. Approximately 750 employees will also transfer as part of the arrangement.

picture27

Caraco and Sun to merge

Home/Pharma News | Posted 01/04/2011

Caraco Pharmaceutical Laboratories announced on 22 February 2011 that it had entered into a merger agreement with generics manufacturer Sun Pharmaceutical Industries and its wholly-owned subsidiary Sun Pharma Global.

picture33

FDA rejects second citizen petition for Teva’s glatiramer acetate drug

Home/Pharma News | Posted 04/06/2010

Teva Pharmaceutical Industries’ glatiramer acetate drug (Copaxone) is indicated for reduction of the frequency of relapses in patients with Relapsing-Remitting Multiple Sclerosis.